Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03760835
PHASE4

Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment

Sponsor: Federico II University

View on ClinicalTrials.gov

Summary

This is a controlled, open study designed to compare the effects of dual-release hydrocortisone preparations versus conventional glucocorticoid therapy on clinical, anthropometric parameters, metabolic syndrome, hormonal profile, bone status, quality of life, reproductive, sexual and psychological functions and treatment compliance in patients affected by congenital adrenal hyperplasia due to 21 OH deficiency.

Official title: Congenital Adrenal Hyperplasia: Innovative Once Daily Dual Release Hydrocortisone Treatment

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2016-08-11

Completion Date

2027-12-31

Last Updated

2025-09-16

Healthy Volunteers

No

Interventions

DRUG

Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)

Treatment of congenital adrenal hyperplasia

DRUG

Dual release hydrocortisone (plenadren)

Treatment of congenital adrenal hyperplasia

Locations (1)

Federico II University

Naples, Italy